Notes
2019 US dollars
Reference
Rosenthal EM, et al. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. Vaccine : 4 Nov 2020. Available from: URL: http://doi.org/10.1016/j.vaccine.2020.10.067
Rights and permissions
About this article
Cite this article
Heplisav-B cost effective versus Engerix-B. PharmacoEcon Outcomes News 867, 16 (2020). https://doi.org/10.1007/s40274-020-7313-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7313-4